ArriVent BioPharma (AVBP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 18, 2025, with voting open until June 17, 2025 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 4, 2025.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of two directors: Zhengbin (Bing) Yao, Ph.D. and Kristine Peterson.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Two director nominees presented for election at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ArriVent BioPharma
- Pivotal NSCLC trials advanced, ADC pipeline expanded, and cash runway extends into 3Q 2027.AVBP
Q4 20255 Mar 2026 - Virtual annual meeting to elect directors and ratify auditor, with updated governance and compensation.AVBPProxy Filing2 Dec 2025
- Net loss increased on higher R&D spend; cash runway extends into mid-2027.AVBPQ3 202510 Nov 2025
- Net loss rose on R&D growth, but strong cash reserves support ongoing clinical progress.AVBPQ2 202511 Aug 2025
- Firmonertinib delivered high response rates and durable CNS benefit in EGFR PACC mutant NSCLC.AVBPStudy Update23 Jun 2025
- Strong clinical progress and $282.9M cash runway support operations into 2026.AVBPQ3 202413 Jun 2025
- Net loss reached $39.3M as cash rose to $298.7M, funding pipeline progress into 2026.AVBPQ2 202413 Jun 2025
- Q1 2025 saw a $64.4M net loss, strong liquidity, and major pipeline and trial progress.AVBPQ1 20256 Jun 2025
- Strong clinical progress and pipeline expansion position ArriVent for pivotal 2025 milestones.AVBPQ4 20245 Jun 2025